PD0332991, a cdk4/6 INHIBITOR, INDUCES TUMOR REGRESSION AND EXTENDS SURVIVAL IN ATYPICAL TERATOID RHABDOID TUMOR (ATRT) AND MEDULLOBLASTOMA MOUSE MODELS

被引：0
|
作者：
Sangar, Michelle Cook [1 ]
Pedro, Kyle [1 ]
Ditzler, Sally H. [1 ]
Girard, Emily [1 ]
Olson, James [1 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
来源：
NEURO-ONCOLOGY | 2013年 / 15卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0151
引用
收藏
页码：40 / 41
页数：2
相关论文
共 40 条
  • [31] Amcenestrant in combination with CDK4/6 inhibitor palbociclib demonstrates synergistic anti-tumor activity in ER plus endocrine-resistant breast cancer xenograft models
    Shomali, Maysoun
    Guo, Zhuyan
    Cheng, Jane
    Sullivan, Amy
    El-Ahmad, Youssef
    Sun, Fangxian
    Sidhu, Sukhvinder
    Lee, Joon Sang
    Cai, Hui
    Pollard, Jack
    Debussche, Laurent
    Soria, Chris
    Bouaboula, Monsif
    CANCER RESEARCH, 2022, 82 (04)
  • [32] Combining OP-3136, a KAT6 inhibitor, with endocrine therapy and CDK4/6 inhibitor enhances anti-tumor activity in ER+/HER2-breast cancer models
    Palanisamy, G.
    Barratt, S.
    Hope, C.
    Robello, B.
    Pena, G.
    Goyal, M.
    Venkateshappa, C.
    Ng, R.
    Ramachandra, M.
    Myles, D.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S89 - S89
  • [33] Anti-tumor activity of CDK2 inhibitor BLU-222 in combination with CDK4/6 inhibitors for overcoming resistance in HR positive and triple negative metastatic breast cancers models
    Luo, Linjie
    Wang, Yan
    Bui, Tuyen
    Li, Mi
    Kim, Serena
    Navarro-Yepes, Juliana
    Kettner, Nicole M.
    Tripathy, Debasish
    Hunt, Kelly K.
    Faia, Kerrie
    Keyomarsi, Khandan
    CANCER RESEARCH, 2024, 84 (06)
  • [34] Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq
    Di Liberto, Maurizio
    Hu, Yang
    Huang, Xiangao
    Lee, Christina Y.
    Wang, Kevin
    Bartlett, Nancy L.
    Ridling, Leann
    Blum, Kristie A.
    Maddocks, Kami J.
    Park, Steven I.
    Ruan, Jia
    Eng, Kenneth
    Galluzzi, Lorenzo
    Leonard, John P.
    Martin, Peter
    Elemento, Olivier
    Chen-Kiang, Selina
    BLOOD, 2019, 134
  • [35] CDK4/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer
    Wang, Laduona
    Wu, Yijun
    Kang, Kai
    Zhang, Xuanwei
    Luo, Ren
    Tu, Zegui
    Zheng, Yue
    Lin, Guo
    Wang, Hui
    Tang, Min
    Yu, Min
    Zou, Bingwen
    Tong, Ruizhan
    Yi, Linglu
    Na, Feifei
    Xue, Jianxin
    Yao, Zhuoran
    Lu, You
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (05) : 1032 - 1046
  • [36] Combination of palbociclib, a potent CDK4/6 inhibitor, with anti-PD1 drug pembrolizumab treatment to promote T-cell mediated glioblastoma tumor cell death under hypoxia
    Xia, Yutong
    Zhou, Lanlan
    Zhao, Shuai
    El-Deiry, Wafik S.
    CANCER RESEARCH, 2023, 83 (07)
  • [37] G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
    Kaitlyn J. Andreano
    Suzanne E. Wardell
    Jennifer G. Baker
    Taylor K. Desautels
    Robert Baldi
    Christina A. Chao
    Kendall A. Heetderks
    Yeeun Bae
    Rui Xiong
    Debra A. Tonetti
    Lauren M. Gutgesell
    Jiong Zhao
    Jessica A. Sorrentino
    Delita A. Thompson
    John E. Bisi
    Jay C. Strum
    Gregory R. J. Thatcher
    John D. Norris
    Breast Cancer Research and Treatment, 2020, 180 : 635 - 646
  • [38] G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
    Andreano, Kaitlyn J.
    Wardell, Suzanne E.
    Baker, Jennifer G.
    Desautels, Taylor K.
    Baldi, Robert
    Chao, Christina A.
    Heetderks, Kendall A.
    Bae, Yeeun
    Xiong, Rui
    Tonetti, Debra A.
    Gutgesell, Lauren M.
    Zhao, Jiong
    Sorrentino, Jessica A.
    Thompson, Delita A.
    Bisi, John E.
    Strum, Jay C.
    Thatcher, Gregory R. J.
    Norris, John D.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) : 635 - 646
  • [39] Analysis of overall survival by tumor response in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, in women with HR+/HER2-metastatic breast cancer (MBC) after chemotherapy for advanced disease
    Cortes, J.
    Rugo, H. S.
    Tolaney, S. M.
    Dieras, V.
    Patt, D.
    Wildiers, H.
    Nanda, S.
    Koustenis, A.
    Dickler, M. N.
    Baselga, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Effects of G1T48, a novel orally bioavailable selective estrogen receptor degrader (SERD), and the CDK4/6 inhibitor, G1T38, on tumor growth in animal models of endocrine resistant breast cancer
    Wardell, Suzanne E.
    Yllanes, Alexander P.
    Baker, Jennifer G.
    Baldi, Robert M.
    Krebs, Taylor K.
    Sorrentino, Jessica
    Bisi, John
    Strum, Jay
    Norris, John D.
    CANCER RESEARCH, 2017, 77
1234